Evidence map›Paper›PMID 39408658›Full record

ArticleInternational journal of molecular sciences2024

In Silico Modeling of Fabry Disease Pathophysiology for the Identification of Early Cellular Damage Biomarker Candidates.

Javier Gervas-Arruga, Miguel Ángel Barba-Romero, Jorge Julián Fernández-Martín, Jorge Francisco Gómez-Cerezo, Cristina Segú-Vergés, Giacomo Ronzoni, Jorge J Cebolla

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Javier Gervas-ArrugaTakeda Development Center Americas Inc., Cambridge, MA 02142, USA.ORCID 0000-0001-5942-5669
Miguel Ángel Barba-RomeroDepartment of Internal Medicine, Albacete University Hospital, 02006 Albacete, Spain.ORCID 0000-0001-5076-607X
Jorge Julián Fernández-MartínDepartment of Internal Medicine, University Hospital Álvaro Cunqueiro, 36312 Vigo, Spain.ORCID 0000-0002-9391-4316
Jorge Francisco Gómez-CerezoDepartment of Internal Medicine, Infanta Sofía University Hospital, 28702 Madrid, Spain.ORCID 0000-0002-3288-5996
Cristina Segú-VergésAnaxomics Biotech S.L., 08007 Barcelona, Spain.ORCID 0000-0002-8215-872X
Giacomo RonzoniTakeda Farmacéutica España S.A., 28046 Madrid, Spain.ORCID 0000-0001-5310-7694
Jorge J CebollaTakeda Farmacéutica España S.A., 28046 Madrid, Spain.ORCID 0000-0001-8727-9179

Funding

Takeda Farmacéutica España S.A. NA
6 · The paper itself

Abstract

Fabry disease (FD) is an X-linked lysosomal disease whose ultimate consequences are the accumulation of sphingolipids and subsequent inflammatory events, mainly at the endothelial level. The outcomes include different nervous system manifestations as well as multiple organ damage. Despite the availability of known biomarkers, early detection of FD remains a medical need. This study aimed to develop an in silico model based on machine learning to identify candidate vascular and nervous system proteins for early FD damage detection at the cellular level. A combined systems biology and machine learning approach was carried out considering molecular characteristics of FD to create a computational model of vascular and nervous system disease. A data science strategy was applied to identify risk classifiers by using 10 K-fold cross-validation. Further biological and clinical criteria were used to prioritize the most promising candidates, resulting in the identification of 36 biomarker candidates with classifier abilities, which are easily measurable in body fluids. Among them, we propose four candidates, CAMK2A, ILK, LMNA, and KHSRP, which have high classification capabilities according to our models (cross-validated accuracy ≥ 90%) and are related to the vascular and nervous systems. These biomarkers show promise as high-risk cellular and tissue damage indicators that are potentially applicable in clinical settings, although in vivo validation is still needed.

Indexed as

BiomarkersComputer SimulationFabry DiseaseMachine LearningHumansLamin Type AProtein Serine-Threonine KinasesBiomarkersLamin Type AProtein Serine-Threonine Kinasesalpha-galactosidase AbiomarkersFabry diseasemachine learningsystems biology

Identifiers

PMID39408658
PMCPMC11477023

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.